Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Adv 2019 Oct 22;3(20):3132-3135
Date
10/28/2019Pubmed ID
31648328Pubmed Central ID
PMC6849956DOI
10.1182/bloodadvances.2019000526Scopus ID
2-s2.0-85074915718 (requires institutional sign-in at Scopus site) 18 CitationsAbstract
Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.
Author List
Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SMAuthor
Timothy Fenske MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic Combined Chemotherapy ProtocolsBendamustine Hydrochloride
Child
Child, Preschool
Cyclophosphamide
Dexamethasone
Doxorubicin
Female
Humans
Infant
Infant, Newborn
Kaplan-Meier Estimate
Lymphoma, Mantle-Cell
Male
Prognosis
Rituximab
Treatment Outcome
Vincristine